Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03564925
Other study ID # WACACF vs Cryo
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2019
Est. completion date December 30, 2021

Study information

Verified date March 2019
Source The Second Affiliated Hospital of Chongqing Medical University
Contact ZHIYU LING, MD
Phone +8613512362075
Email lingzy1977@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this randomized clinical trial is to compare the efficacy and safety of wide area circumferential ablation using contact force catheter with cryoballoon ablation for the treatment of paroxysmal atrial fibrillation.


Description:

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with stroke, reductions in quality of life and overall survival. Previous studies have shown that cryoballoon ablation was noninferior to radiofrequency ablation with respect to efficacy for the treatment of patients with drug-refractory paroxysmal atrial fibrillation. However, the pulmonary vein isolation for radiofrequency catheter ablation in previous studies was done around each pulmonary-vein antrum, and it's not wide area circumferential ablation. Moreover, the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing was not performed in most of previous studies. We hypothesize that wide area circumferential ablation with contact force catheter and combined catheter ablation the potential atrial triggers and/or other atrial arrhythmias induced by aggressive induction is more effective than cryoballoon ablation in patients with paroxysmal atrial fibrillation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date December 30, 2021
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Symptomatic PAF with at least two episodes and at least one episode documented (30 seconds episode length, documented by ECG within last 12 months).

Documented treatment failure for effectiveness of at least one anti-arrhythmic drug(AAD Type I or III, including ß-blocker and AAD intolerance).

2. = 18 and = 75 years of age.

3. Patients who are mentally and linguistically able to understand the aim of the trial and to show sufficient compliance in following the trial protocol.

4. Patient is able to verbally acknowledge and understand the associated risks, benefits, and treatment alternatives to therapeutic options of this trial: cryoballoon ablation system or standard RF ablation technique. The patients, by providing informed consent, agree to these risks and benefits as stated in the patient informed consent document. All the details have been presented to him and he has signed the informed consent form for the trial.

Exclusion Criteria:

Exclusion criteria related to a cardiac condition

1. Patients with prosthetic valves.

2. Any previous LA ablation or surgery.

3. Any cardiac surgery or percutaneous coronary intervention (PCI) within three months prior to enrollment.

4. Unstable angina pectoris.

5. Myocardial infarction within three months prior to enrollment.

6. Symptomatic carotid stenosis.

7. Chronic obstructive pulmonary disease with detected pulmonary hypertension.

8. Any condition contraindicating chronic anticoagulation.

9. Stroke or transient ischemic attack within six months prior to enrollment.

10. Any significant congenital heart defect corrected or not (including atrial septal defects or PV abnormalities) but not including patent foramen ovale.

11. New York Heart Association (NYHA) class III or IV congestive heart failure.

12. EF < 35 % (determined by echocardiography within 60 days of enrollment as documented in patient medical history).

13. Anteroposterior LA diameter > 55 mm (by trans-thoracic echocardiography (TTE or TEE) within three months to prior enrollment).

14. LA thrombus (TEE diagnostic performed on admission). Intracardiac thrombus.

15. PV diameter > 26 mm in right sided PVs.

16. Mitral prosthesis.

17. Hypertrophic cardiomyopathy

18. 2° (Type II) or 3° atrioventricular block.

19. Brugada syndrome or long QT syndrome.

20. Arrhythmogenic right ventricular dysplasia.

21. Sarcoidosis.

22. PV stent.

23. Myxoma.

Exclusion criteria based on laboratory abnormalities

1. Thrombocytosis (platelet count > 600,000 / µl), thrombocytopenia (platelet count < 100,000 / µl).

2. Any untreated or uncontrolled hyperthyroidism or hypothyroidism.

3. Severe renal dysfunction (stage V, requiring or almost requiring dialysis, glomerular filtration rate (GFR) < 15 ml / min).

Study Design


Intervention

Procedure:
Wide area circumferential ablation
Wide area circumferential ablation with contact force catheter will be performed in Patients allocated in this group,the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing will be performed. If frequent atrial premature beats are found beyond pulmonary vein, activation mapping will be performed for eliminating the triggers. If atrial tachycardias(ATs)are induced, activation mapping the ATs and ablation will be performed. Electrical isolation of pulmonary veins and elimination the triggers and ATs induced by isoproterenol or programmed stimulation and burst pacing are the endpoints of ablation
Cryoballoon ablation
In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a single-shot delivery of coolant to the balloon.

Locations

Country Name City State
China The Second Affilliated Hospital of Chongqing Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
The Second Affiliated Hospital of Chongqing Medical University

Country where clinical trial is conducted

China, 

References & Publications (1)

Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KR, Elvan A, Arentz T, Bestehorn K, Pocock SJ, Albenque JP, Tondo C; FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 Jun 9 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to first documented recurrence of atrial arrhythmias a blanking period of three months will be maintained after the initial procedure 12 months
Secondary time to the first occurrence of each of the components of the primary outcome a blanking period of three months will be maintained after the initial procedure 12 months
Secondary all-cause death all-cause death 12 months
Secondary Arrhythmia-related death Arrhythmia-related death 12 months
Secondary total procedural duration time of total procedural 12 months
Secondary total time of fluoroscopy total time of fluoroscopy 12 months
Secondary time to recurrent atrial fibrillation (AF) a blanking period of three months will be maintained after the initial procedure 12 months
Secondary time to first cardiovascular hospitalization a blanking period of three months will be maintained after the initial procedure 12 months
Secondary number of cardiovascular hospitalizations (over-night stays) a blanking period of three months will be maintained after the initial procedure 12 months
Secondary quality of life changes at 12 months compared to baseline with the evaluation of the MOS item short from health survey(SF-36) 12 months
Secondary time to first symptomatic AF recurrence a blanking period of three months will be maintained after the initial procedure 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A